Danaher Corporation (NYSE:DHR) is a diversified medical products supplier that caters to the needs of the diagnostics, biotechnology, life sciences, and other industries. The key to the firm's hypothesis, and one that can deliver either tailwinds or headwinds to the shares is its bioprocessing business. Danaher Corporation (NYSE:DHR) is one of the few large scale companies in the world, and with bioprocessing thought to lead to the creation of novel healthcare products such as gene therapies, the company has a wide moat in this sector. Danaher Corporation (NYSE:DHR) is an acquisition driven firm that relies on retained earnings to expand into new industries. These include potential treatments for Alzheimer's and Duchenne dystrophy, and any blockbuster treatments created with Danaher Corporation (NYSE:DHR)'s help could lead to sizeable catalysts for the firm.